

Striving for Consensus: Optimizing the Selection and Sequencing of Therapy for Patients with Relapsed/Refractory Follicular Lymphoma — CAR T-Cell Therapy

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following agents is approved for follicular lymphoma (FL)?
 - a. Axicabtagene ciloleucel (axi-cel)
 - b. Tisagenlecleucel (tis-cel)
 - c. Lisocabtagene maraleucel (liso-cel)
 - d. All of the above**
 - e. None of the above
2. What was the approximate median progression-free survival for patients with FL who received axi-cel in the ZUMA-5 study?
 - a. 25 months
 - b. 40 months
 - c. 62 months**
 - d. 88 months
3. What outcome was observed for patients with high-risk features (eg, POD24, bulky disease) in the Phase II ELARA study evaluating tis-cel for patients with relapsed/refractory FL who received ≥ 2 lines of therapy or who experienced disease relapse after autologous stem cell transplantation?
 - a. Patients with high-risk features had a substantially diminished overall response rate (ORR) and complete response (CR) rate compared to the overall population
 - b. Patients with high-risk features maintained similarly high ORR and CR rates compared to the overall population**
 - c. Patients with high-risk features derived significantly more durable responses compared to the overall population
4. What was the approximate ORR in the third-line or later cohort of patients with FL treated with liso-cel in the TRANSCEND FL study?
 - a. 35%
 - b. 54%
 - c. 76%
 - d. 97%**
5. Which of the following agents has the highest reported incidence of any-grade cytokine release syndrome in clinical trials?
 - a. Tis-cel
 - b. Axi-cel**
 - c. Liso-cel